Loading cancer entity…
Loading cancer entity…
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07823985 | Preoperative Embolization for Highly Vascular Brain Tumors | not yet recruiting | N/A | 55 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT00005902 | Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease | active not recruiting | — | 250 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04458935 | Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma | completed | — | 25 | National Eye Institute (NEI)NIH | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06638931 |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials
| recruiting |
| Phase 2 |
| 28 |
| Instituto do Cancer do Estado de São PauloOTHER |
| 1 |
| Apr 15, 2026 |
| clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05424016 | Propranolol and Von Hippel-Lindau Disease(PRO-HEB) | recruiting | N/A | 85 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02120040 | Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System(PsychoVHL) | completed | N/A | 42 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT00052013 | Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 | completed | Phase 2 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00589784 | Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | completed | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01015300 | Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease | terminated | Early Phase 1 | 1 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 11, 2012 | clinicaltrials |